Novoprotein Scientific Inc. (688137.SH) has issued a risk warning announcement regarding severe abnormal fluctuations in its stock trading, according to the company.

The company disclosed that revenue from RNA vaccine drug-related products in 2025 accounted for 11.38% of total product revenue, representing a relatively low proportion.

Its AI-enabling high-throughput wet lab and data package services remain in the early stage of market development, with related business revenue accounting for less than 2% of the company's total operating revenue as of the first half of 2026.

Given that the application of AI in the pharmaceutical R&D industry is still in its infancy, there are risks including rapid technological iteration, lengthy industry validation cycles, and significant difficulties in commercial implementation.

The company's future revenue and profit realization from related businesses face substantial uncertainty.